Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Director's Dealing 2016

Mar 2, 2016

30583_dirs_2016-03-02_5290fb7b-a01c-4139-8503-1ae3d201ae8d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2016-02-29

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-02-29 Common Stock F 192982 $81.87 Disposed 350500 Direct
2016-03-01 Common Stock S 5021 $84.3259 Disposed 345479 Direct
2016-03-01 Common Stock S 2151 $84.2178 Disposed 343328 Direct
2016-03-01 Common Stock S 2828 $84.235 Disposed 340500 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 25758 Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed December 4, 2015.

F2: The price in column 4 is an average weighted price. The price actually received ranged from $81.35 to $87.11. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price in column 4 is an average weighted price. The price actually received ranged from $81.40 to $86.61. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.s.

F4: The price in column 4 is an average weighted price. The price actually received ranged from $81.50 to $86.98. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.